RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Outcomes Similar with BEV or CET Added to Induction CT for mCRC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 17
OP 17
DO 10.1177/155989771422014
UL http://mdc.sagepub.com/content/14/22/17.1.abstract
AB First-line treatment for metastatic colorectal cancer (mCRC) is combination chemotherapy (CT) plus a monoclonal antibody (mAB). The Cetuximab and/or Bevacizumab Combined With Combination Chemo—therapy in Treating Patients With Metastatic Colorectal Cancer [CALGB/SWOG 80405; NCT00265850] study examined whether a strategy that blocked endothelial growth factor receptors with the mAB cetuximab (CET) or blocked vascular endothelial growth factors with the mAB bevacizumab (BEV) provided a greater improvement in the effectiveness of CT.